TCI Wealth Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-140
Closed -$2.62K 2576
2022
Q4
$2.62K Hold
140
﹤0.01% 1905
2022
Q3
$3K Hold
140
﹤0.01% 1780
2022
Q2
$3K Buy
+140
New +$3.95K ﹤0.01% 1817
2021
Q4
Sell
-32
Closed -$3K 2400
2021
Q3
$3K Sell
32
-2
-6% -$201 ﹤0.01% 1945
2021
Q2
$4K Buy
34
+18
+113% +$1.73K ﹤0.01% 1584
2021
Q1
$2K Buy
+16
New +$2.1K ﹤0.01% 1774
2018
Q4
Sell
-250
Closed -$17K 1530
2018
Q3
$17K Hold
250
0.01% 533
2018
Q2
$12K Hold
250
0.01% 608
2018
Q1
$14K Buy
250
+83
+50% +$4.49K 0.01% 559
2017
Q4
$8K Buy
+167
New +$10.4K ﹤0.01% 677
2017
Q3
Sell
-8
Closed -$1K 1348
2017
Q2
$1K Hold
8
﹤0.01% 1147
2017
Q1
$1K Sell
8
-75
-90% -$5.98K ﹤0.01% 1109
2016
Q4
$7K Sell
83
-17
-17% -$1.54K ﹤0.01% 703
2016
Q3
$11K Hold
100
0.01% 552
2016
Q2
$11K Sell
100
-33
-25% -$4.01K 0.01% 544
2016
Q1
$14K Hold
133
0.01% 507
2015
Q4
$11K Hold
133
0.01% 557
2015
Q3
$9K Sell
133
-9
-6% -$784 0.01% 532
2015
Q2
$14K Buy
142
+7
+5% +$748 0.01% 465
2015
Q1
$13K Buy
135
+122
+938% +$11.8K 0.01% 415
2014
Q4
$1K Hold
13
﹤0.01% 807
2014
Q3
$1K Buy
+13
New +$1.62K ﹤0.01% 805

Other funds holding INO

TCI Wealth Advisors's INO Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Inovio Pharmaceuticals (INO) in Q1 2023, closing a stake of 140 shares — an estimated $2.62K sold.

TCI Wealth Advisors first reported a position in INO in Q3 2014 and held it in 22 quarters. The position peaked at $17K in Q3 2018. 174 funds tracked by Wall St. Rank hold INO as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Inovio Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 140 Inovio Pharmaceuticals shares in Q1 2023, an estimated $2.62K.
  • TCI Wealth Advisors first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 22 quarters.
  • TCI Wealth Advisors's Inovio Pharmaceuticals position peaked at $17K in Q3 2018.
  • 174 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.